

Estimate change	↔
TP change	↑
Rating change	↔

Bloomberg	COFORGE IN
Equity Shares (m)	443
M.Cap.(INRb)/(USDb)	841.8 / 8.9
52-Week Range (INR)	2022 / 1008
1, 6, 12 Rel. Per (%)	10/62/21
12M Avg Val (INR M)	4793

Financials & Valuations (INR b)

Y/E Mar	FY26	FY27E	FY28E
Sales	164.0	248.5	298.7
EBIT Margin (%)	14.4	16.0	16.4
PAT	14.7	25.0	32.4
EPS (INR)	35.2	56.9	72.7
Adj. PAT	17.0	25.9	33.0
Adj. EPS (INR)	40.2	58.7	74.0
Adj. EPS Gr. (%)	102.5	45.8	26.1
BV/Sh. (INR)	226.9	541.5	588.8

Ratios

RoE (%)	16.5	14.9	13.0
RoCE (%)	19.5	14.4	11.8
Payout (%)	43.8	24.6	27.5

Valuations

P/E (x)	54.0	33.4	26.1
P/BV (x)	8.4	3.5	3.2
EV/EBITDA (x)	25.9	15.7	12.9
Div Yield (%)	0.8	0.7	1.1

Shareholding pattern (%)

As On	Sep-26	Jun-26	Sep-25
Promoter	0.0	0.0	0.0
DII	43.7	42.6	54.9
FII	24.8	24.3	34.1
Others	31.5	33.1	11.0

FII Includes depository receipts

CMP: INR1,900 **TP: INR2,370 (+25%)** **Buy**

A quarter for integration

Margin push encouraging as benefits from AI continue

- COFORGE reported 2QFY27 organic revenue growth of 3.8% QoQ in CC terms, above our estimate of 3.5% QoQ CC. The company reported an order intake of USD1,040m (up 102.3% YoY) with eight large deal wins. Consolidated EBIT margin stood at 16%, in line with our estimate.
- Consolidated adjusted PAT stood at INR6.3b (up 12.5% QoQ/67.8% YoY), in line with our estimate.
- 1HFY27 revenue/EBIT/adj. PAT grew 52.1%/78.8%/59.8% YoY. In 2HFY27, we expect revenue/EBIT/adj. PAT growth of 51.5%/58.1%/47.6% YoY in INR terms. **We value COFORGE at 32x FY28E EPS with a TP of INR2,370**, implying a 25% potential upside. We reiterate our **BUY** rating on the stock.

Our view: Strong order book supports growth acceleration in 2H

- **Deal momentum remains strong, supporting growth visibility:** Coforge reported a record quarterly order intake of USD1.04b, up 51% QoQ and 102% YoY, with eight large deal wins. The next 12-month executable order book rose 45% YoY to a record USD2.4b. With eight or more large deal wins targeted in 3QFY27, deal momentum is expected to support growth visibility. Most large deals are proactively sourced and solution-led, limiting direct pricing competition.
- **Encora integration nearing completion; growth expected to accelerate in 2HFY27:** YoY organic growth has decelerated over the past two quarters, partly reflecting the Encora integration, with Encora's revenue remaining broadly flat QoQ at USD147-148m in 2QFY27. With integration largely complete, Encora's growth is expected to converge with Coforge's from 3QFY27. Encora's margin expansion is also ahead of the acquisition plan, while a strong deal pipeline, including the largest deal currently being pursued with an Encora client and expected to close in 3Q or 4Q, provides further growth opportunities.
- **Margin trajectory improving, with further expansion levers:** Margin gains have so far been supported by G&A efficiency, with G&A growing only 15.6% YoY against revenue and sales and marketing growth of ~52% YoY. Further improvement is expected from AI-led efficiency and high utilization, currently at 82.4% vs. ~86% for peers. Gross margin expansion is expected to become more visible from 4QFY27. We expect consolidated EBIT margins at 16% in FY27E and build in 40bp improvement in FY28E. The margin upgrade, alongside continued investment in sales and solutioning, supports the view that profitability gains are not being pursued at the expense of growth.
- **Organic growth led by BFSI and government; healthcare and high-tech decline:** Organic QoQ CC revenue growth was led by government outside India (+20.8% QoQ), BFSI (+8.3%), insurance (+3.6%), emerging verticals (+2.3%), and travel, transportation and hospitality (+1.8%). Healthcare and high-tech declined 6.4%. **Organic growth led by BFSI and government; healthcare and high-tech decline:** Organic QoQ CC revenue growth was led by government outside India (+20.8% QoQ), BFSI (+8.3%), insurance (+3.6%), emerging verticals (+2.3%), and travel, transportation and hospitality (+1.8%). Healthcare and high-tech declined 6.4%.

Abhishek Pathak - Research Analyst (Abhishek.Pathak@MotilalOswal.com)

Keval Bhagat - Research Analyst (Keval.Bhagat@MotilalOswal.com) | **Suket Kothari - Research Analyst** (Suket.Kothari@MotilalOswal.com)

Investors are advised to refer through important disclosures made at the last page of the Research Report.

Motilal Oswal research is available on www.motilaloswal.com/Institutional-Equities, Bloomberg, Thomson Reuters, Factset and S&P Capital.

- **Cash conversion on track despite temporary collection delays:** FCF-to-PAT conversion stood at 89% in 2Q, with **100% conversion targeted for FY27**. OCF-to-EBITDA (~42%) **conversion** has been **affected by the transfer of contracts** from US entities to India as part of Encora's legal entity rationalization and tax structuring, resulting in temporary delays in invoicing and collections.

Valuation and view


- We expect COFORGE to be the **growth leader** within our coverage universe, and we reiterate it as our top pick. Strong deal wins, continued execution, improving cash conversion, and EBIT margin guidance upgrade, along with further expansion in FY28, provide **confidence in the medium-term growth outlook**.
- We keep our estimates unchanged and raise our **target multiple to 32x FY28E EPS** (earlier 29x), arriving at a TP of INR2,370, implying 25% upside. The higher multiple reflects **improved visibility** from strong deal wins and structurally higher margins. We reiterate our **BUY** rating on the stock.

Miss on revenue, margins in line; FY27 EBIT margin guidance upgraded from 15.5% to 16%

- Organic revenue grew 3.8% QoQ CC (vs. our estimate of 3.5% QoQ CC).
- Revenue rose 10.9% QoQ CC (est. 12% CC). Reported USD growth was 10.1% QoQ.
- Growth was led by the Government outside India, BFS, Healthcare and Hi-Tech vertical (up 20.8%/14.3%/13.7% QoQ).
- Order intake was USD1,040m (up 102.3% YoY). 12-month executable order book rose 45.4% YoY to USD2.38b. It signed eight large deals in 2Q, the highest for any quarter.
- FY27 consolidated EBIT margin guidance has been upgraded from 15.5% to 16.0%. For FY28, the company expects to further improve its EBIT margin to 17%.
- EBIT margin was 16%, in line with our estimates of 16%.
- Utilization was down 10bp QoQ at 82.4%. Net employee addition stood at 1,137, up 2.5% QoQ. Attrition remained flat QoQ at 10.4%.
- Adj. PAT stood at INR6.3b (up 12.5% QoQ/67.8% YoY) vs. our estimates of INR6.4b.
- FCF to Adj. NI stood at 89% vs. 95% in 1QFY27.

Key highlights from the management commentary

- Management sees **acute industry pricing pressure** from AI-led deflation, with time-and-material economics weakening as automation reduces labor content.
- COFORGE expects to be the **industry growth leader for the third consecutive year** in FY27, which will be the 10th year of its current leadership team.
- Management aims to **accelerate growth** from hereon and reiterates that growth remains the first priority over margins.
- A **second client has crossed USD100m in annualized revenue**, while a large deal was signed during the quarter at one of the company's highest-margin accounts.
- Management expects **eight or more large deals in 3QFY27**, the shortest quarter, potentially surpassing the 2Q record.
- Client outcomes include an AI quote agent reducing turnaround time from **three weeks to under five days**, and the release of **15,000 business hours** at a pharma client.
- Management expects the commercial model to shift from effort-based to **value-based pricing** as proactive, outcome-led proposals gain share.

Exhibit 1: Management has reiterated its target of 100%+ FCF-to-PAT conversion for FY27


Source: Company, MOFSL

Quarterly Performance (IND-AS)

Y/E March	FY26				FY27E				FY26*	FY27E*
(Consolidated)	1Q*	2Q	3Q*	4Q*	1Q*	2Q	3QE	4QE		
Rev. (USD m)	444	462	481	489	592	652	682	709	1,870	2,635
QoQ (%)	10.1	4.0	4.1	1.7	21.1	10.1	4.5	4.0	29.1	40.9
Revenue (INR m)	37,044	39,857	42,315	44,504	55,277	61,708	64,475	67,054	1,64,027	2,48,513
YoY (%)	56.0	30.2	29.9	30.0	49.2	54.8	52.4	50.7	35.9	51.5
GPM (%)	34.0	34.0	33.6	34.4	34.3	34.1	34.1	34.1	33.8	34.1
SGA (%)	16.5	15.7	15.3	13.8	13.9	13.5	13.5	13.5	15.3	13.6
EBITDA (INRm)	6,471	7,282	7,735	9,168	11,233	12,697	13,282	13,813	30,464	51,025
EBITDA Margin (%)	17.5	18.3	18.3	20.6	20.3	20.6	20.6	20.6	18.6	20.5
EBIT (INRm)	4,879	5,563	6,027	7,368	8,822	9,847	10,380	10,796	23,645	39,845
EBIT Margin (%)	13.2	14.0	14.2	16.6	16.0	16.0	16.1	16.1	14.4	16.0
Other income	-477	18	-710	-582	-803	-686	-645	-671	-2,058	-2,805
ETR (%)	21.7	23.8	22.8	-6.6	24.3	24.3	24.0	24.0	13.4	24.1
Minority Interest	-390.0	-496.0	-465.0	-539.0	-131.0	-168.0	-130.0	-130.0	-1,890.0	-559.0
Reported PAT	2,471	3,757	2,501	6,123	5,186	5,881	6,809	7,141	14,854	25,017
QoQ (%)	1.2	22.9	-3.1	79.7	-14.4	12.5	8.0	4.9		
YoY (%)	35.1	62.6	62.5	116.6	83.2	67.8	87.0	9.2	74.5	52.1
Adj. PAT	3,057	3,757	3,640	6,541	5,602	6,303	6,809	7,141	16,996	25,852
EPS (INR)	7.2	8.9	8.6	15.5	13.3	14.1	15.3	16.0	40.2	58.7

Note: *Figures are adjusted for the change in the revenue recognition accounting policy. In addition, 1QFY27 figures include two months of contribution from Encora.

Key Performance Indicators

Y/E March	FY26				FY27		FY26
	1Q	2Q	3Q	4Q	1Q	2Q	
Revenue (QoQ CC %)	8.0	5.9	4.4	2.0	22.3	10.9	
Margins							
Gross Margin	34.0	34.0	33.6	34.4	34.3	34.1	33.8
EBIT Margin	13.2	14.0	14.2	16.6	16.0	16.0	14.4
Net Margin	6.7	9.4	5.9	13.8	9.4	9.5	9.1
Operating metrics							
Headcount	34,187	34,896	35,341	35,777	46,228	47,365	35,777
Attrition (%)	11.3	11.4	10.9	10.8	10.4	10.4	10.8
Deal Win TCV (USD b)	507	514	593	648	691	1,040	2,262
Key Verticals (YoY USD %)							
BFS	33.0	17.4	16.4	(1.7)	18.9	29.5	15.0
Insurance	20.2	(1.1)	(3.1)	6.8	17.0	19.6	4.9
Travel and Transport	93.0	61.0	55.8	48.5	24.0	22.4	62.3
Key Geographies (YoY USD %)							
North America	73.1	31.5	24.9	25.6	45.3	53.8	35.7
Europe	23.3	7.0	2.6	6.5	20.8	20.1	9.2



Key highlights from the management commentary

Demand outlook

- Management sees **acute industry pricing pressure** from AI-led deflation, with time-and-material economics weakening as automation reduces labor content.
- Coforge expects to be the **industry growth leader for the third consecutive year** in FY27, which will be the 10th year of the current leadership team.
- Management aims to **accelerate growth** from hereon and reiterates that growth remains the first priority over margins.
- A **second client has crossed USD100m in annualized revenue**, while a large deal was signed during the quarter at one of the company's highest-margin accounts.
- Management expects **eight or more large deals in 3QFY27**, the shortest quarter, potentially surpassing the 2Q record.
- Client outcomes include an AI quote agent reducing turnaround time from **three weeks to under five days**, and the release of **~15,000 business hours** at a pharma client.
- Management expects the commercial model to shift from effort-based to **value-based pricing** as proactive, outcome-led proposals gain share.
- The demand slowdown is attributed mainly to **slower procurement-led RFPs**, while enterprise appetite for AI-led transformation continues to strengthen.
- Management calls 2Q a **critical tipping point** in internal AI adoption, prompting the margin guidance upgrade.
- Enterprises extract the most AI value from redesigning and automating workflows, shifting the opportunity from supplying effort to owning business outcomes.
- New deals are expected to ramp up almost immediately, with no long-gestation programs.
- Most large deals are sole-sourced and proactive, led by an onsite solutioning engine, helping avoid price-led competition.
- Consolidated revenue grew 10.9% QoQ CC (10.1% in USD and 11.6% in INR) to USD652.2m (INR61.7b), marking the first full quarter of Encora consolidation.
- Organic growth stood at 3.8% QoQ CC, with Encora contributing an implied ~USD147-148m, broadly flat on a full-quarter basis and in line with expectations.
- Encora's growth is expected to mirror Coforge's from 3QFY27, as integration is complete and both businesses now operate as a single unit.
- AI-led engineering, data, integration and cloud contributed **~86% of cons. revenue**.
- Order intake exceeded **USD1b (+51% QoQ and +102% YoY)**, marking only the second time in company history, led by Europe at USD485m and North America at USD455m.
- One of the large deals was a **USD230m UK public sector engagement**, signed in Jul'26.
- **BFS:** BFSI grew **8.3% QoQ CC organically**, the strongest performance among the large verticals, with two of the eight large deals coming from the segment. A North American wealth management platform deployed an **AI trade assistant** that increases advisor capacity without incremental headcount.
- **Insurance:** Insurance grew **3.6% QoQ CC**, with AI adoption remaining strong as legacy modernization is a key use case. A North American P&C insurer migrated legacy integration services to AWS microservices through an **AI-powered Mod Squad**, enabling ~30% faster delivery.

- **Healthcare & Hi-Tech:** Healthcare & hi-tech declined **6.4% QoQ CC organically**, although the Encora-led healthcare account remains a top-10 client and is growing strongly. Two of the eight large deals came from hi-tech, while the Encora healthcare and hi-tech pipeline supports growth from 3QFY27.
- **Government (overseas):** Government outside India grew **20.8% QoQ CC**, the fastest across verticals, with three of the eight large deals coming from public sector.
- Revenue growth of 40–50% was absorbed in G&A **without incremental hiring**, aided by technology adoption across finance, HR and IT.
- Coforge runs **520+ AI engagements for 225+ clients**, with **260+ agents deployed in live operations**.
- **Neuron and Momentum Blue** (forward-deployed engineer unit), supported by Mod Squads, anchor the AI delivery model.
- The largest program involves migrating **12m lines of code to Google Cloud over ~4.5 years**, with execution largely AI-led.
- An AI drilling advisor at an energy services client now plans **half of new well projects**, reducing analysis time from weeks to hours.
- Encora's margin expansion is **ahead of the acquisition plan**, with its largest healthcare client and the largest pipeline deal both within the Encora business.
- Partnerships were expanded with **Pega** for own-brand offerings and **AWS** through a forward-deployed engineer pilot, with AWS co-investing.

Margin performance and other comments

- Consolidated EBIT margin stood at 16%, ahead of the 15.5% guidance, while standalone EBIT margin was ~17%.
- FY27 EBIT margin guidance was raised to 16% from 15.5%, with 4QFY27 targeted at 17% and margins expected to remain at or above 17% in FY28.
- EBITDA margin stood at 20.5% in 1HFY27, with FY27 guidance of 20.5-21% maintained.
- Combined G&A improved to 6.3% of revenue from 6.6% in 1QFY27. YoY G&A growth was only ~15.6%, against revenue growth of ~53%, while S&M grew ~52%.
- Gross margin is expected to see a material uplift from 3Q or 4QFY27 as Momentum Blue investments scale.
- Hedge losses stood at USD10.2m, broadly in line with 1QFY27. Mark-to-market losses are expected at USD7m in 3Q and USD1.2m in 4Q, followed by nil thereafter.
- Exceptional items stood at USD5.9m, relating to legal entity rationalization and tax structuring, and are expected to be nil from 3QFY27.
- Total integration costs were ~USD17m vs. the guided USD15-16m, owing to higher-than-expected overseas tax planning costs and the rationalization of ~95 entities.
- Nil exceptional items, lower hedge losses and a 17% EBIT margin exit rate imply significant upside to 4QFY27 exit EPS, with management indicating ~INR19-20.
- The steady-state tax rate is guided at 23-24%, while minority interest is likely to stay unchanged, relating to the Coforge DPS JV, in which the client holds a 20% stake.
- FCF/PAT stood at 89% in 2QFY27 (USD 53.8m) and 92% in 1HFY27, with FY27 guidance of 100%+ maintained.

Exhibit 2: Govt Outside India, Healthcare and BFS led the growth during the quarter

Verticals (QoQ, USD%)	2QFY24	3QFY24	4QFY24	1QFY25	2QFY25	3QFY25	4QFY25	1QFY26	2QFY26	3QFY26	4QFY26	QFY27	2QFY27
BFS	4.0	3.3	4.3	-2.3	17.4	-1.1	15.4	-0.7	3.7	-2.0	-2.6	20.1	12.9
Insurance	2.3	-1.3	-2.2	-5.6	23.2	4.1	-7.7	1.6	1.3	2.0	1.7	11.3	3.7
Transportation	2.3	-2.4	-1.5	6.6	26.9	5.7	9.0	32.0	5.8	2.3	3.9	10.2	4.4
Govt Outside India				7.3	22.5	-4.0	10.8	7.1	-0.3	-5.0	21.1	-3.1	19.3
Healthcare and Hi-tech*										9.3	11.4	82.1	12.3
Others	0.5	4.0	-30.6	11.4	56.2	-14.0	-13.4	-1.2	11.9	19.4	-6.6	15.7	13.0

Note: New vertical reporting started from 3QFY26, Healthcare also included Encora's business, which is double the COFORGE's healthcare business; Source: Company, MOFSL

Exhibit 3: US & APAC contributed to growth

Geography(QoQ, USD%)	2QFY24	3QFY24	4QFY24	1QFY25	2QFY25	3QFY25	4QFY25	1QFY26	2QFY26	3QFY26	4QFY26	1QFY27	2QFY27
US	1.7	-4.3	2.0	8.6	39.9	7.4	0.9	14.1	6.2	2.1	1.5	32.0	12.4
EMEA	2.8	4.5	-0.1	-4.7	16.3	7.0	-2.7	1.9	0.9	2.6	1.0	15.5	0.3
APAC	3.2	15.2	-9.3	-3.1	23.4	-6.7	38.1	13.4	1.7	15.9	3.8	-9.6	20.9

Source: Company, MOFSL

Valuation and view

- We expect COFORGE to be the **growth leader** within our coverage universe, and we reiterate it as our top pick. Strong deal wins, continued execution, improving cash conversion, and EBIT margin guidance upgrade, along with further expansion in FY28, provide **confidence in the medium-term growth outlook**.
- We keep our estimates unchanged and raise our **target multiple to 32x FY28E EPS** (earlier 29x), arriving at a TP of INR2,370, implying 25% upside. The higher multiple reflects **improved visibility** from strong deal wins and structurally higher margins. We reiterate our **BUY** rating on the stock.

Exhibit 4: Revisions to our estimates

	Revised		Earlier		Change	
	FY27E	FY28E	FY27E	FY28E	FY27E	FY28E
INR/USD	94.3	96.0	95.3	96.0	-1.1%	0.0%
USD Revenue (m)	2,635	3,111	2,667	3,163	-1.2%	-1.6%
Growth (%)	40.9	18.1	42.6	18.6	-170bps	-50bps
EBIT margin (%)	16.0	16.4	16.0	16.1	0bps	30bps
Adj. PAT (INR m)	25,852	32,966	25,824	32,505	0.1%	1.4%
Adj. EPS	58.7	74.0	58.6	72.9	0.1%	1.5%

Source: MOFSL

Exhibit 5: Operating metrics

	2QFY25	3QFY25	4QFY25	1QFY26	2QFY26	3QFY26	4QFY26	1QFY27	2QFY27
Revenue mix Geography-wise (%)									
Americas	55.1	56.0	54.7	56.7	57.9	56.8	56.7	61.8	63.1
EMEA	33.8	34.2	32.2	29.8	28.9	28.5	28.3	27.0	24.6
RoW	11.1	9.8	13.1	13.5	13.2	14.7	15.0	11.2	12.3
Revenue mix Vertical-wise (%)									
BFS	29.4	27.5	30.7	27.7	27.6	26.0	24.9	24.7	25.3
Insurance	19.1	18.8	16.8	15.5	15.1	14.8	14.8	13.6	12.8
Transportation	18.1	18.1	19.1	22.9	23.3	22.9	23.4	21.3	20.2
Manufacturing/Media/Others	25.9	21.0	17.6	15.8	17.0	19.5	17.9	17.1	17.5
Revenue mix (%)									
Top Clients contribution (%)									
Top – 5	18.7	19.8	18.0	20.7	21.0	21.0	21.8	18.0	18.1
Top -10	28.2	30.0	27.7	29.3	30.8	30.7	31.4	26.1	26.4
Fresh order Intake - USD m									
USA	245	294	1,828	272	281	304	437	364	455
EMEA	184	93	170	140	122	194	156	260	485
RoW	86	114	128	95	110	95	55	67	101
Deals signed - USD m	516	501	2,126	507	514	593	648	691	1,040
Executable Order Book (NTM) - USD m	1,105	1,365	1,505	1,550	1,635	1,717	1,752	2,228	2,380
Employee metrics									
Billable Personnel	30,434	30,981	31,354	32,013	32,710	33,178	33,643	43,421	44,652
Sales and Marketing	575	583	586	594	622	617	577	687	673
Others	1,474	1,530	1,557	1,580	1,564	1,546	1,557	2,120	2,040
Total	32,483	33,094	33,497	34,187	34,896	35,341	35,777	46,228	47,365
Utilization	82.2	81.3	82	82.1	82.3	81.7	82.5	82.5	82.4
Attrition	11.7	11.9	10.9	11.3	11.4	10.9	10.8	10.4	10.4

Source: Company, MOFSL

Financials and valuations

Income Statement							(INR m)
Y/E March	FY22	FY23	FY24	FY25	FY26	FY27E	FY28E
Sales	64,320	80,146	90,089	1,20,733	1,64,027	2,48,513	2,98,679
Change (%)	37.9	24.6	12.4	34.0	35.9	51.5	20.2
Cost of revenue	43,736	54,059	60,179	79,999	1,08,527	1,63,705	1,96,583
Gross Profit	20,584	26,087	29,910	40,734	55,500	84,808	1,02,096
SGA expenses	8,527	11,438	13,694	23,516	25,036	33,783	40,322
RSU costs	633	587	1,046	1,742	1,979	1,883	2,389
EBITDA	11,424	14,062	15,170	17,218	30,464	51,025	61,775
% of Net Sales	17.8	17.5	16.8	14.3	18.6	20.5	20.7
Depreciation	2,272	2,585	2,972	4,276	6,819	11,180	12,843
EBIT	9,152	11,477	12,198	12,942	23,645	39,845	48,931
% of Net Sales	14.2	14.3	13.5	10.7	14.4	16.0	16.4
Other Income	-266	-630	-1,153	19	-2,058	-5,031	-4,820
PBT	8,886	10,847	11,045	12,961	21,587	34,814	44,111
Tax	1,468	2,208	2,209	3,326	2,583	8,131	10,587
Rate (%)	16.5	20.4	20.0	25.7	12.0	23.4	24.0
Extraordinary Items	269	1,188	261	0	2,260	1,107	557
Minority Interest	530	513	276	1,240	1,890	559	558
Adjusted PAT	6,888	8,126	8,560	9,742	16,996	25,852	32,966
Change (%)	44.0	18.0	5.3	13.8	74.5	52.1	27.5

Balance Sheet							(INR m)
Y/E March	FY22	FY23	FY24	FY25	FY26	FY27E	FY28E
Share Capital	609	611	618	669	672	886	886
Reserves	26,722	30,214	35,648	63,123	94,704	2,35,998	2,60,047
Net Worth	27,331	30,825	36,266	63,792	95,376	2,36,884	2,60,933
Loans	3,365	3,382	3,399	67	1,167	49,707	31,467
Minority Interest	983	874	1,003	19,498	1,430	1,193	674
Other liabilities	6,073	4,360	5,094	13,750	14,147	21,434	25,760
Capital Employed	37,752	39,441	45,762	97,107	1,12,120	3,09,218	3,18,835
Net Block	4,452	4,455	4,470	7,682	9,425	9,481	8,207
CWIP	86	46	232	24	33	33	33
Intangibles	14,821	16,299	16,133	49,726	55,114	1,74,936	1,72,367
Investments	0	0	0	0	0	0	0
Deferred tax assets	7,976	9,970	14,217	19,860	25,184	38,156	45,858
Curr. Assets	22,209	26,064	26,025	43,508	59,058	1,37,703	1,50,150
Debtors	13,894	16,131	18,039	25,771	39,700	46,298	55,644
Cash & Bank Balance	4,468	5,699	3,213	7,956	10,936	78,674	79,216
Investments	67	88	139	2,333	56	56	56
Other Current Assets	3,780	4,146	4,634	7,448	8,366	12,675	15,234
Current Liab. & Prov	11,792	17,393	15,315	27,375	36,694	51,091	57,780
Trade payables	6,160	6,481	8,062	9,883	17,754	31,643	38,030
Other liabilities	5,316	10,552	6,836	16,786	17,953	17,953	17,953
Provisions	316	360	417	706	987	1,495	1,797
Net Current Assets	10,417	8,671	10,710	16,133	22,364	86,612	92,370
Application of Funds	37,752	39,441	45,762	97,107	1,12,120	3,09,218	3,18,835

Financials and valuations

Ratios

Y/E March	FY22	FY23	FY24	FY25	FY26	FY27E	FY28E
EPS	15.7	16.4	19.7	19.9	35.2	56.9	72.7
Cash EPS	21.1	22.5	26.7	33.2	51.0	82.3	101.5
Book Value	65.0	73.3	86.3	151.8	226.9	541.5	588.8
DPS	10.4	12.8	15.2	15.2	15.4	14.0	20.0
Payout %	66.4	77.9	77.3	76.5	43.8	24.6	27.5

Valuation (x)

P/E	121.3	115.7	96.7	95.6	54.0	33.4	26.1
Cash P/E	90.3	84.3	71.2	57.3	37.2	23.1	18.7
EV/EBITDA	69.8	56.6	52.7	45.8	25.9	15.7	12.9
EV/Sales	12.4	9.9	8.9	6.5	4.8	3.2	2.7
Price/Book Value	29.2	25.9	22.0	12.5	8.4	3.5	3.2
Dividend Yield (%)	0.5	0.7	0.8	0.8	0.8	0.7	1.1

Profitability Ratios (%)

RoE	25.0	23.1	24.1	13.9	16.5	14.9	13.0
RoCE	23.6	22.9	22.8	13.4	19.5	14.4	11.8

Turnover Ratios

Debtors (Days)	65	68	69	66	73	63	62
Fixed Asset Turnover (x)	15.4	18.0	20.2	19.9	19.2	26.3	33.8

Cash Flow Statement

(INR m)

Y/E March	FY22	FY23	FY24	FY25	FY26	FY27E	FY28E
CF from Operations	9,089	10,532	11,834	15,060	24,538	34,112	43,457
Cash for Working Capital	-1,433	-1,027	-2,800	-2,689	-6,621	-2,195	-8,591
Net Operating CF	7,656	9,505	9,034	12,371	17,917	31,917	34,866
Net Purchase of FA	-1,475	-1,537	-2,598	-5,572	-2,953	-9,000	-9,000
Free Cash Flow	6,181	7,968	6,436	6,799	14,964	22,917	25,866
Net Purchase of Invest.	-8,089	-1,179	120	-18,911	-1,395	-1,39,815	0
Net Cash from Invest.	-9,564	-2,716	-2,478	-24,483	-4,348	-1,48,815	-9,000
Proceeds from Equity	51	18	-3,516	21,831	-111	1,40,029	0
Proceeds from LTB/STB	2,139	-1,315	-573	19	-5,395	50,767	-16,406
Dividend Payments	-3,748	-4,285	-4,781	-5,097	-5,431	-6,160	-8,917
Cash Flow from Fin.	-1,558	-5,582	-8,870	16,753	-10,937	1,84,636	-25,324
Net Cash Flow	-3,466	1,207	-2,314	4,641	2,632	67,740	541
Exchange difference	-65	24	-172	102	348	0	0
Opening Cash Bal.	7,998	4,467	5,698	3,212	7,955	10,935	78,674
Add: Net Cash	-3,531	1,231	-2,486	4,743	2,980	67,740	541
Closing Cash Bal.	4,467	5,698	3,212	7,955	10,935	78,674	79,216

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

NOTES

Explanation of Investment Rating	
Investment Rating	Expected return (over 12-month)
BUY	>=15%
SELL	< - 10%
NEUTRAL	< - 10 % to 15%
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall be within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

Disclosures

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412 and BSE enlistment no. 5028. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on www.motilaloswal.com. MOFSL is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products and is a member of Association of Portfolio Managers in India (APMI) for distribution of PMS products. Details of associate entities of Motilal Oswal Financial Services Ltd. are available on the website at <http://onlinereports.motilaloswal.com/Dormant/documents/Associate%20Details.pdf>

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at <https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx>. As per Regulatory requirements, Research Audit Report is uploaded on www.motilaloswal.com > MOFSL-Important Links > MOFSL Research Analyst Compliance Audit Report.

A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com. Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg. No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

For U.S.

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts"), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement. The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets (Singapore) Pte. Ltd. ("MOCMSPL") (UEN 201129401Z), which is a holder of a capital markets services license and an exempt financial adviser in Singapore. This report is distributed solely to persons who (a) qualify as "institutional investors" as defined in section 4A(1)(c) of the Securities and Futures Act of Singapore ("SFA") or (b) are considered "accredited investors" as defined in section 2(1) of the Financial Advisers Regulations of Singapore read with section 4A(1)(a) of the SFA. Accordingly, if a recipient is neither an "institutional investor" nor an "accredited investor", they must immediately discontinue any use of this Report and inform MOCMSPL.

In respect of any matter arising from or in connection with the research you could contact the following representatives of MOCMSPL. In case of grievances for any of the services rendered by MOCMSPL write to grievances@motilaloswal.com.

Nainesh
Email: nainesh.rajani@motilaloswal.com
Contact: (+65) 8328 0276

Rajani

Specific Disclosures

- Research Analyst and/or his/her relatives do not have a financial interest in the subject company(ies), as they do not have equity holdings in the subject company(ies). MOFSL has financial interest in the subject company(ies) at the end of the week immediately preceding the date of publication of the Research Report: Yes.
Nature of Financial interest is holding equity shares or derivatives of the subject company
- Research Analyst and/or his/her relatives do not have actual/beneficial ownership of 1% or more securities in the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report.
MOFSL has actual/beneficial ownership of 1% or more securities of the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report: No
- Research Analyst and/or his/her relatives have not received compensation/other benefits from the subject company(ies) in the past 12 months.
MOFSL may have received compensation from the subject company(ies) in the past 12 months.
- Research Analyst and/or his/her relatives do not have material conflict of interest in the subject company at the time of publication of research report.
MOFSL does not have material conflict of interest in the subject company at the time of publication of research report.
- Research Analyst has not served as an officer, director or employee of subject company(ies).
- MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months.
- MOFSL has not received compensation for investment banking /merchant banking/brokerage services from the subject company(ies) in the past 12 months.
- MOFSL may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company(ies) in the past 12 months.
- MOFSL may have received compensation or other benefits from the subject company(ies) or third party in connection with the research report.
- MOFSL has not engaged in market making activity for the subject company.

The associates of MOFSL may have:

- financial interest in the subject company
 - actual/beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance.
 - received compensation/other benefits from the subject company in the past 12 months
 - any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.
 - acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
 - be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)
 - received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.
 - Served subject company as its clients during twelve months preceding the date of distribution of the research report.
- The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report
- Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, nor its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI, enlistment as RA with Exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263; www.motilaloswal.com. Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal, Email Id: na@motilaloswal.com, Contact No.:022-40548085.

Grievance Redressal Cell:

Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	query@motilaloswal.com
Ms. Kumud Upadhyay	022 40548082	servicehead@motilaloswal.com
Mr. Ajay Menon	022 40548083	am@motilaloswal.com
Mr. Neeraj Agarwal	022 40548085	na@motilaloswal.com
Mr. Siddhartha Khemka	022 50362452	po.research@motilaloswal.com

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412, BSE enlistment no. 5028, AMFI registered Mutual Fund Distributor and SIF Distributor: ARN : 146822. IRDA Corporate Agent – CA0579, APMI: APRN00233. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dpgrievances@motilaloswal.com.